- Home
- MHO vs OGN Comparison
MHO vs OGN Comparison
Compare MHO & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHO
- OGN
- Stock Information
- Founded
- MHO 1976
- OGN 1923
- Country
- MHO United States
- OGN United States
- Employees
- MHO N/A
- OGN N/A
- Industry
- MHO Homebuilding
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- MHO Consumer Discretionary
- OGN Health Care
- Exchange
- MHO Nasdaq
- OGN Nasdaq
- Market Cap
- MHO 3.6B
- OGN 4.0B
- IPO Year
- MHO 1986
- OGN N/A
- Fundamental
- Price
- MHO $137.39
- OGN $15.86
- Analyst Decision
- MHO Buy
- OGN Hold
- Analyst Count
- MHO 3
- OGN 3
- Target Price
- MHO $197.50
- OGN $21.33
- AVG Volume (30 Days)
- MHO 322.7K
- OGN 4.3M
- Earning Date
- MHO 01-29-2025
- OGN 02-13-2025
- Dividend Yield
- MHO N/A
- OGN 7.06%
- EPS Growth
- MHO 8.04
- OGN 120.97
- EPS
- MHO 18.62
- OGN 5.04
- Revenue
- MHO $4,271,981,000.00
- OGN $6,409,000,000.00
- Revenue This Year
- MHO $11.89
- OGN $3.29
- Revenue Next Year
- MHO $4.70
- OGN $1.93
- P/E Ratio
- MHO $7.49
- OGN $3.15
- Revenue Growth
- MHO N/A
- OGN 4.21
- 52 Week Low
- MHO $109.92
- OGN $13.87
- 52 Week High
- MHO $176.18
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- MHO 48.26
- OGN 56.02
- Support Level
- MHO $135.10
- OGN $15.29
- Resistance Level
- MHO $141.94
- OGN $16.23
- Average True Range (ATR)
- MHO 3.77
- OGN 0.52
- MACD
- MHO 1.95
- OGN 0.08
- Stochastic Oscillator
- MHO 76.64
- OGN 80.12
About MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise the most significant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.